How to choose a longevity clinic: what to fix before you buy frontier tools

An operator's guide to order. Two models, five much marketed tools, and the one thing that tells you whether a longevity offer is serious: what somebody measured before anybody infused anything.

My version of this began as a procurement exercise. I was costing out the diagnostics and the so called frontier equipment for the health venture I'm building in Portugal, and what I typed into the spreadsheet read like a highlights reel of everything the sector currently sells. Chambers. Protocols. Panels. Infusions.

Then I put that spreadsheet in front of my medical advisory board, line by line, and watched the same look cross the same faces. Interesting biology, they said, but for which person. Promising, they said, but resting on what strength of evidence. Would you honestly offer this, they asked, before you had done anything about someone's blood pressure, their sleep, their strength.

That was uncomfortable in a specific way. I'm the founder who is meant to be building the honest version of this category, and I had absorbed the sales narrative before I understood the underlying reality. If the story catches me while I'm staring at a capital expenditure sheet, I don't rate the odds for a busy, worried buyer reading a glossy menu in a waiting room.

So I went back to first principles. What genuinely helps, what belongs where, and what an honest stack of longevity care would look like drawn out in full. This page is my answer, written for anybody who has been handed a list of options and felt an unease they couldn't quite name.

This is an educational and strategic perspective, not personal medical advice. The views are the author's own and not statements by Atlas Cove Lda.

The buyer I keep meeting in every city

She is somewhere between her mid forties and her late fifties. Successful, short on time, quietly anxious about her health, and curious about optimisation. More than one wearable. A continuous glucose monitor worn at some point. A folder of laboratory results and longevity panels that keeps getting thicker. Ask her for a number and she has it: resting heart rate, heart rate variability, steps, minutes of deep sleep.

What she has never had is one joined up conversation about what all of that is supposed to sum to. Not the readings themselves, but what they mean for her blood pressure, her strength, her aerobic capacity and what she actually does in an ordinary week. And nobody has told her where, inside that picture, an infusion or a chamber would honestly sit.

If you recognise yourself in that, or if you are building or funding a business that sells to her, this page is written for you. Nothing here is a judgement on anyone who has already bought some of it. I nearly bought all of it, with company money, on purpose.

What the shiny end of the market is really promising

Walk through the wealthy districts of most large cities and the new architecture of longevity is easy to spot. Marble reception areas. Laboratories selling biomarker packages. Whole body imaging suites. Counters that sell peptides the way a bar sells cocktails. Pressurised pods. Lounges where a bag of something drips into your arm and the word cellular appears on the wall.

Some of what sits behind that frontage is genuine progress, and I want to say so before I say anything critical. Preventive care has finally become socially acceptable rather than eccentric. What we understand about metabolism, inflammation and the biology of ageing has moved a very long way past eat less and move more.

The problem isn't the people who work in these places, and it certainly isn't the customers. It's an incentive. A gleaming intervention is easy to describe, easy to price and easy to book. The things with the deepest human evidence behind them are none of those. Follow that incentive for a few years and you arrive somewhere uncomfortable: the distance between what a buyer believes she is purchasing and what the science can currently demonstrate keeps getting wider.

Closing that distance doesn't require biochemistry. It requires two mental models. One tells you how care ought to be ordered, the other how solid the proof underneath a claim really is. Everything after that is detail.

The first model: a building with three floors

If somebody handed me a whiteboard and asked me to draw responsible longevity care, I would draw a building with three storeys.

Floor one, the foundations

Behavioural and physiological, and dull enough that almost nobody sells it well. This is the layer carrying the strongest long term evidence in humans.

Muscle you have built and kept, and the strength that goes with it.
Cardiorespiratory capacity.
Blood pressure, glucose and lipids sitting where they should sit.
Sleep, and a circadian rhythm that holds from week to week.
Little smoking, and no habitual heavy drinking.
Relationships that are stable and real, and less isolation.

Floor two, structured medical prevention

Ordinary medicine, used early and used intelligently rather than waiting for something to break.

Screening and imaging where they are actually indicated.
Hypertension, lipids and diabetes risk managed the way the evidence says to manage them.
Established drugs used where they are known to change what happens to a person.
Nutritional and psychological support built into the care rather than bolted on.

Floor three, the frontier

The experimental storey. Better stories, more uncertainty, more risk.

Intravenous longevity drips.
NAD+ infusions, and the precursors sold alongside them.
Hyperbaric oxygen sold for anti ageing.
Injectable peptides from the grey market.
Plasma exchange, and everything marketed as blood cleansing.

In a rational system a person climbs the building in sequence. Foundations, then prevention, then the frontier. In the pitch decks, and in the first draft of my own equipment list, that sequence is frequently inverted. People are offered the top storey while the ground floor is still an empty site.

A clinic that has not gone near your blood pressure, your sleep and your strength before it goes near a drip is not practising longevity. It is staging it.

Treat that as the minimum standard worth defending. Foundations measured and addressed before anything gets infused. It's a low bar, and a great deal of the sector is quietly stepping over it.

The second model: how far the claim has actually climbed

The other model is a ladder, and it has three rungs. Whenever a longevity claim is put in front of you, the only question worth asking first is which rung it is standing on.

Mechanism. Something interesting occurs inside a cell or along a pathway. Usually in an animal, sometimes in a dish. The sentence sounds like this: the molecule switches on the pathway in mice.
Biomarker. A laboratory value or an imaging measure shifts in the direction we take to be favourable. The sentence sounds like this: the protocol made telomeres in blood cells longer.
Outcome. People live longer, keep their independence for longer, or run into serious disease less often, measured over a stretch of time that means something. The sentence sounds like this: fewer cardiovascular events, better survival, more years of function.

Almost everything on the third floor is standing on rung one or rung two. Almost all of the marketing, and the shopping list I wrote before my advisers took it apart, presents those tools as though they were standing safely on rung three.

Worth unfolding, because this is where buyers get caught. A moving biomarker is not nothing. It is a reason to run a bigger study. What it is not is proof that the thing the marker stands in for has improved in you. That a favourable laboratory value must bring a favourable change in how long you live, and how well, is exactly the assumption the third rung exists to test rather than to inherit.

A claim that never gets above mechanisms and biomarkers doesn't get to wear an outcome's halo.

Using a rung one or rung two tool is not unethical in itself. Charging outcome prices, and making outcome promises, when all you hold is a mechanism and a moved marker, is.

Five questions that tell you who you are dealing with

These are the building and the ladder folded together into something you can say out loud in a consulting room.

Where does this sit on the ladder for my situation: is it a mechanism, a biomarker, or an outcome?
Which storey of the building is this, foundation, medical prevention, or frontier?
Imagine this option were unavailable. What would you put in front of me instead, to shift my risk over the next twenty years?
What could go wrong, said plainly, for somebody in my position?
How will the two of us know whether it worked, and at what point would we stop?

A serious operator will not mind them. If the answers come back vague, or the room goes defensive, the thing that has gone wrong is not your curiosity.

Now watch the same shape repeat across five very different tools. Strong narrative, real mechanism, thin outcome evidence, and a buyer whose ground floor is still a building site.

The same pattern, five times over

Intravenous drips: a clinical tool in a lifestyle costume

The promises on the wall: immune boost, detox, cellular repair. The honest tier: strong outcome level evidence inside hospitals, for dehydration and for malnutrition. Minimal evidence for longevity in people who are basically well.

Intravenous therapy saves lives in emergency and inpatient medicine every day, and I have no argument with it on the second storey. For a generally healthy person who walks into a drip lounge because the word longevity is on the door, the situation is not the same. There is no solid long term data showing that routine vitamin infusions, given to people who eat normally and absorb normally, add years or add function.

Iron, and why it earns its own warning

An iron infusion is essential when somebody is genuinely deficient and cannot fix it by mouth. Elective iron given to a person whose stores are fine is a different proposition, and calling it an upgrade does not make it a safe one.

Iron that is loose in the system feeds the Fenton reaction. It meets hydrogen peroxide, and out of that come radicals reactive enough to damage cells and tissue. So you can be paying for something described as a detox while quietly raising oxidative stress in the very organs you were hoping to protect.

Deficiency documented, work up done, indication clear: in that case an infusion inside a medical setting is entirely appropriate. For the tired executive whose laboratory results came back unremarkable, it is risk absorbed without proven long term return.

Three questions do most of the work when a drip is offered under the longevity heading. Which deficiency are we correcting, and can you show me that in my own results. Would this still be your recommendation if my levels were normal. Beyond feeling better this afternoon, what are you expecting over twenty years, and where does that expectation come from.

NAD+: the biomarker that got promoted

The promises: mitochondrial reset, youth drip, brain reboot. The honest tier: mechanistic and animal data that are strong, human findings that are early and mixed, and nothing yet at outcome level in adults who are already well.

NAD+ genuinely sits at the centre of energy metabolism and DNA repair, and the pathways around it do appear to change with age in particular tissues. That is the mechanism, and it is a real one.

Short term human work does show that an infusion, or a precursor taken by mouth, can lift measured NAD+ or move a metabolic marker. That is the biomarker, and it is also real.

What nobody holds yet is durable evidence that driving NAD+ hard in otherwise healthy adults adds years or prevents serious disease events.

The reaction that never appears in the marketing

Rapid NAD+ infusions frequently cause real distress while they are running. Tightness in the chest, cramping in the abdomen, a sensation people describe as impending doom. The likeliest explanation is smooth muscle activation as the infusion arrives quickly in the system.

For somebody already well built, who understands they are placing an experimental bet at the margin, that may be an acceptable trade. For a person who smokes, sleeps five hours and doesn't train, and who is trying to buy back time, it is a poor way to spend both risk and money.

Calling that a reversal of ageing, on the strength of one metabolite shifting in a blood sample, isn't optimism. It's inflation.

Three questions to put to a clinic proposing it. Is what you have here mechanism and biomarker, or do you hold outcome data in people resembling me. What proportion of your clients get the acute reaction, and how is it managed. If I decline, name the three things you would put ahead of it.

Hyperbaric oxygen: real medicine, stretched story

The promises: reversed biological age, regeneration. The honest tier: strong outcome level data for particular conditions, early biomarker level data for ageing, and nothing directly about lifespan.

Hyperbaric oxygen is not pseudoscience, and I want to be careful here. It is standard care for the bends, for particular wounds that refuse to close, and for a short list of other clearly defined indications. Second storey medicine, properly earned.

The longevity story leans on early protocols where structured hyperbaric exposure lengthened telomeres and cut back senescent immune cells in older participants. Those are biomarker shifts. Interesting ones. They are not the sentence you are now younger. Telomere length changing inside one population of blood cells does not automatically mean ageing has been reversed across an entire person.

The risks are unglamorous, which is why they get left off the page. Pressure injuries to ears and sinuses. Seizures at high exposures. Fire risk in an oxygen rich environment, particularly outside a hospital grade installation.

Inside a tightly controlled medical setting, for a carefully selected person whose foundations are already strong, hyperbaric oxygen may be a reasonable experiment. Sold from a unit in a retail park as reverse your age in ten sessions, it has been marketed a very long way beyond its proof.

Three questions, then. Does my case appear on the established list, or is this an experiment. Which serious risks attach to the pressure and protocol used in this particular room. What change, beyond a well designed report, would count as success.

Peptides: pharmacology without the guardrails

The promises: cellular rejuvenation, fat loss, optimised hormones. The honest tier is unusually wide here. It runs all the way from licensed medicines with substantial trial evidence behind them down to laboratory compounds carrying next to no human safety record.

At the licensed end sit medicines like the GLP-1 agonists, backed by large regulated programmes and written indications. At the other end sit compounds such as BPC-157, CJC-1295 and TB-500, commonly sold under a research label, or marked as unsuitable for people, while everyone involved understands what they are actually for.

Because so much of this trades outside normal pharmaceutical channels, it slips past the quality controls those channels exist to impose. Independent testing and regulatory notices have turned up labels that do not match the vial, impure and truncated peptide chains, bacterial contamination, endotoxins, and contents bearing no relationship to what was ordered.

What you are left holding is a paradox: effects like a drug, oversight like a supplement.

Inside a formal medical programme or a clinical trial, with real sourcing and real monitoring, certain peptides may be worth investigating for somebody already well optimised. Ordering vials from an online reseller because a podcast used the word healing is not the same activity, whatever the molecule turns out to be. So before anything is injected, establish whether this is a licensed medicine for your own indication or a research grade product, who made it and to which standard, and how benefit and side effects will be followed, stopping rule included.

Plasma exchange: large procedure, small proof

The promises: microplastic removal, immune rejuvenation, the next frontier. The honest tier: outcome level evidence that is strong in defined autoimmune and haematologic disease, speculation at mechanism level for longevity in well adults, and nothing demonstrated about lifespan or healthspan in that second group.

Therapeutic plasma exchange is a real hospital procedure. There are conditions of the immune system and the blood in which it saves a life. Legitimate second storey medicine, again.

The longevity narrative rests on two ideas. That thinning out pro ageing factors circulating in the blood achieves something durable, and that microplastics or other contaminants can be physically taken out to useful effect. As hypotheses these are plausible. What they are not, yet, is backed by clear human outcome data in people who are otherwise well.

There is an irony sitting in the hardware. The circuits that carry your blood around outside your body during a cleansing procedure are themselves made of plastic, and plastic can leach plasticisers. So you accept an invasive intervention carrying vascular and bleeding risk, in pursuit of a benefit that stays theoretical.

If it is pitched to you, ask which diagnosis or risk is being addressed in your own case, what has been shown in people resembling you rather than in mice, and how the procedural risk is set against that, including who they would turn away.

Five different tools, one repeating shape. Heavy equipment, light outcomes, sold as though the top rung had already been reached.

Why the layer that works is the layer nobody sells

So why does the industry lean quite so hard on expensive and theoretical technology? Because the interventions that genuinely move long term outcomes are difficult to package and difficult to monetise. That is the whole explanation, and it deserves sitting with.

Pull back to the large human datasets, the cohorts that follow people for decades, and a different picture assembles itself. The capacities and behaviours that keep appearing alongside lower mortality and less disability are almost embarrassingly ordinary. Long running Finnish work on sauna use, for instance, finds lower cardiovascular and all cause mortality among people who do something as unremarkable as sitting in a hot room on a regular basis. Not because heat is magic. Because simple things done repeatedly compound.

Read across that literature and the most robust drivers of a healthy long life look suspiciously like the ground floor of my building.

Keeping the muscle and the strength you have, and adding to it.
Building cardiorespiratory capacity and then not losing it.
Holding blood pressure, glucose and lipids inside healthy ranges.
Protecting sleep and the rhythm around it.
Cutting smoking and heavy drinking.
Staying inside relationships that are real rather than performed.

None of that photographs well. None of it fits neatly into a weekend. The margins are thinner. And it is still the engine.

For most people, most of the time, the frontier is not advanced optimisation at all. It is a diversion around the handful of things with proven impact.

The minority who could reasonably consider the experimental layer share one profile, spelled out in the next section. They are playing for small gains at the edge of a finished structure, and that is a legitimate thing to be doing. A great many others are being sold that edge as a starting position. If that reads as blunt, good. This subject deserves bluntness more than it deserves flattery.

If you have actually built the foundation

Say you can honestly claim all of it. Most weeks you do both resistance and aerobic work, and that has been true for years. Metabolic markers stable and well controlled. Sleep at seven to nine hours on a schedule that mostly holds. No smoking, and alcohol isn't how you switch off in the evenings. At least a working grip on your stress and your relationships.

Then you are close to the group for whom frontier tools can sensibly be treated as experimental bets at the margin. Four rules make that defensible rather than an expensive hobby.

Treat the frontier as risk budget, not as necessity. Assume the compounding still comes from the foundation. A chamber, an infusion, a vial, a circuit: each gets a defined allocation of risk and money. None of them is the strategy.
Insist on knowing your rung. For every single tool: mechanism, biomarker, or outcome. If it has never climbed past the first two, treat it as what it is.
Require medical grade process rather than atmosphere. Actual clinicians. Written protocols. Dosing, monitoring, and stated stopping criteria. We stop if this happens, or if we haven't seen that by then.
Be honest with yourself about the motive. Curiosity is a legitimate reason to try something, and so is optimisation. Just don't dress a mechanistic experiment up as a guaranteed dividend. Naming the real motive keeps both you and your clinician on the right side of the line.

Let me be exact about what I am not saying. Nothing at this layer is unethical by nature. Openly labelled, resting on a foundation that genuinely exists, inside a bounded budget for risk, it is reasonable to explore as optional upside. Several of these are excellent medicine within their proven indications, which is a different sentence from excellent longevity products, and that difference is the point.

The ethical failure isn't the existence of these tools. It's selling them as foundations to people who don't have one yet.

What a defensible operator would actually do

Which is where the conversation has to move next. Less arguing about whether drips are good or bad, more describing a model that could survive scrutiny. Five commitments.

Sequence care by storey. Every client begins on the ground floor. Nothing from the third storey goes on the menu routinely until the essentials are at least being measured and worked on: blood pressure, sleep, lipids, glucose, and strength or some usable proxy for fitness.
Put every tool on the ladder in writing. For each one, a short summary the client can read: what is known at outcome level, what is promising at biomarker level, what is still theory.
Write down who qualifies and who doesn't. Not everybody is offered everything. Some tools stay reserved for people who have cleared defined basics or meet defined clinical criteria.
Follow outcomes past the feeling in the room. Strength, fitness, metabolic markers, sleep and functional capacity, tracked across years rather than weeks, alongside whatever frontier intervention is running.
State risk as loudly as promise. Oxidative stress from iron. Contamination in grey market peptides. Barotrauma and fire risk with hyperbaric oxygen. Vascular risk in plasma exchange. In the conversation, not in the small print.

A business that leads with infusions and never once measures your strength is not yet in the longevity business, whatever the signage says. It is selling something else under a borrowed name.

There is a commercial argument here too. Operators who get this right will build the more durable companies: less regulatory exposure, fewer disillusioned former clients, and a compounding dataset on what actually shifts outcomes. Inside the European Union, and in Portugal in particular, where the rules governing medical practice are already tight and heading tighter, treating the first two storeys as compulsory isn't idealism. It's risk management.

A mature version of this sector will eventually be required to sequence and to disclose. The only open question is who decides to behave now as though that future had already arrived.

The incentive nobody puts in the brochure

The market as it stands runs on two confusions, and both of them are profitable. The first blurs mechanisms and biomarkers into implied outcomes. The second treats the optimised edge case and the average under served buyer as though the same menu should be handed to both.

The answer is not less innovation, and I would be a strange person to be building this venture if it were. The answer is more honesty about two things: where each tool truly sits on the ladder, and which storey, and which kind of person, it suits.

What we have normalised is selling the sensation of safety to people who are in fact purchasing structured uncertainty. A large share of them should have been offered sleep, strength and glucose control first.

That meeting with my advisory board, and the doubtful expressions travelling down my shopping list, was the useful kind of humbling. The kind that makes you rebuild a model from the ground rather than patch it.

Innovation will shape what preventive medicine becomes. But the scarce resource in longevity is not another device, another molecule or another chamber. It is trust. Trust gets earned by telling somebody what you sell and also telling them, honestly, whether they belong anywhere near it.

Until your blood pressure, your sleep and your strength have been touched, the drip can wait.

Where Atlas Cove sits in this

The venture I'm building, and the writing I publish alongside it, live on exactly that line: optimistic about what is coming, unsentimental about shortcuts. How we think about ordering the work is set out in our method, and the application exists partly so the sequencing conversation happens before anybody commits to anything. Related arguments run through how longevity actually scales, the overbuilt middle layer, and the wider business of health.

The first reader of this argument was me, and it changed my own plan. I'm publishing it so your tuition to the marketing machine comes in cheaper than mine did.

Questions readers ask

Should I have an intravenous drip for longevity?

In hospital medicine, intravenous therapy is outcome level care and saves lives. Marketed for longevity to a generally healthy person, it is a different claim, and no solid long term data supports it in people who eat and absorb normally. Ask which deficiency is being corrected, and whether you can see it in your own results.

Does NAD+ therapy reverse ageing?

The mechanism is real and the biomarker moves. Missing is durable evidence that driving NAD+ hard in adults who are already well adds years or prevents serious disease. Announcing a reversal of ageing because one metabolite shifted is marketing inflation. Fast infusions also frequently cause acute discomfort, which rarely makes it into the promotional material.

Is hyperbaric oxygen legitimate?

For the bends, for wounds that will not close, and for a short list of other defined indications, entirely. The anti ageing case rests on early biomarker findings, telomere length and senescent immune cells, which is not the same statement as a person having become younger. The risks, including ear and sinus injury, seizures at high exposure and fire in oxygen rich rooms, belong in the conversation.

How do I know whether my foundations are done?

Use the list above. Years of consistent resistance and aerobic training, metabolic markers stable, seven to nine hours of sleep on a schedule that holds, no smoking, no nightly sedation with alcohol, a basic grip on stress and relationships. If several are missing, the frontier is not where your next decision belongs.

Are frontier tools always a bad idea?

No, and I am careful about that. Sitting on a foundation that genuinely exists, used openly, inside a defined risk budget, with the rung of the evidence stated honestly, they are a reasonable thing to explore as optional upside. The failure is never the tool itself. It is selling that tool as a foundation to somebody who hasn't got one.

This is an educational and strategic perspective, not personal medical advice. The views are the author's own and not statements by Atlas Cove Lda.

How we sequence the work

Lisa Wuerden · Co-Founder

Co-founder, brand and product